Price Alert

SELLAS Life Sciences Grou... (SLS)

NASDAQ: SLS · Real-Time Price · USD

1.78

0.00 (0.00%)

At close: Sep 04, 2025, 3:59 PM

1.79

0.56%

After-hours: Sep 04, 2025, 07:59 PM EDT

0.00% (1D)

Bid	1.75
Market Cap	187.43M
Revenue (ttm)	n/a
Net Income (ttm)	-26.26M
EPS (ttm)	-0.3
PE Ratio (ttm)	-5.93
Forward PE	-4.94
Analyst	Strong Buy

Ask	1.8
Volume	1,542,000
Avg. Volume (20D)	2,638,767
Open	1.78
Previous Close	1.78
Day's Range	1.75 - 1.82
52-Week Range	0.77 - 2.27
Beta	2.27

About SLS

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol SLS

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for SLS stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

News

2 weeks ago · seekingalpha.com

Sellas Life Sciences: SLS009's Phase 2 Sets Up A Promising 2026

SELLAS Life Sciences is developing GPS as a WT1 immunotherapy, which is in Phase 3 for AML. However, I believe their SLS009 candidate as a CDK9 inhibitor further gives the stock broad AML applicabilit...

1 month ago · zacks.com

SELLAS Life Sciences Group (SLS) Upgraded to Buy: What Does It Mean for the Stock? (Revised)

SELLAS Life Sciences Group (SLS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

2 months ago · zacks.com

Galena Biopharma (SLS) Upgraded to Buy: What Does It Mean for the Stock?

Galena Biopharma (SLS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.